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Abstract 
Introduction: Methylene blue dye has been used worldwide successfully with few complications 
in breast surgery.  We present two different complications involving methylene blue: 1) skin 
and parenchymal necrosis when dye was injected in a subdermal fashion and 2) Mycoplasma 
infection caused by contaminated methylene blue in breast reduction surgery.   
Methods: W e   p r e s e n t   t w o   c a s e s   s e e n   a t   t h e   U n i v e r s i t y   o f   A r i z o n a   d u r i n g   2 0 0 8   a n d   r e f e r r e d   t o  
a breast surgeon for management.  We evaluated and managed complications of methylene 
blue dye injected by 2 referring surgeons for different indications.  A review of the literature 
was performed. 
Results: T h e   f i r s t   c a s e   i s   a   6 7   y e a r   o l d   f e m a l e   d i a g n o s e d   w i t h   i n f i l t r a t i n g   d u c t a l   c a r c i n o m a   o f   t h e  
l e f t   b r e a s t   f o r   w h i c h   s h e   w a s   t r e a t e d   b y   h e r   i n i t i a l   s u r g e o n   w i t h   l e f t   s e g m e n t a l   m a s t e c t o m y  
and sentinel node biopsy.  The operating surgeon injected methylene blue in a subareolar 
subdermal fashion (distant from the primary tumor); unfortunately the patient suffered skin 
and breast necrosis requiring multiple surgical debridements and finally achieving delayed 
primary closure. The second case is a 45 year old female with infiltrating lobular carcinoma 
with a history of Mycoplasma infection secondary to methylene blue injected for breast re-
duction surgery. She required multiple debridements and had granulomas masquerading as 
cancer on MRI that confounded her extent of disease. 
Conclusions: The use of methylene blue dye in breast surgery is not without r i s k .     I n   b o t h   c a s e s  
methylene blue was responsible for complications requiring surgical debridement for local 
wound problems.  In each case severe necrosis and infection were present.  Methylene blue 
may cause not only significant morbidity, but may also produce cosmetically unsatisfactory 
results. 
Key words: Methylene blue, blue dye, complications, breast, surgery, adverse reactions, sentinel 
node 
Introduction 
Methylene blue dye (MBD) has been successfully 
used worldwide with few complications in patients 
undergoing breast surgery. We herein describe 2 dif-
ferent complications in 2 patients: 1) skin and paren-
chymal necrosis when MBD was injected subdermally 
and 2) Mycoplasma infection caused by contaminated 
MBD in breast reduction surgery.  
S e v e r a l   p u b l i c a t i o n s   a d v o c a t e   t h e   u s e   o f   s u b-
dermal  MBD  injections  for  SLN  mapping  without 
complications  (1-3);  however,  several  publications 
r e p o r t   c o m p l i c a t i o n s   r a n g i n g   f r o m   b l u e   s t a i n i n g   o f   t h e  
skin and fat necrosis (4-6).   
The  American  Society  of  Clinical  Oncology 
( A S C O )   g u i d e l i n e s   a d v o c a t e   t h e   u s e   o f   b l u e   d y e   i n  Journal of Cancer 2011, 2 
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conjunction  with  radioisotope  for  SLN  mapping  as 
t h i s   c o m b i n e d   s t r a t e g y   y i e l d s   t h e   h i g h e s t   r a t e s   o f  
successful SLN  mapping (7).  Some surgeons prefer 
MBD  over  Lymphazurin  (isosulphan  blue  dye)  be-
cause  Lymphazurin  is  more  expensive,  sometimes 
u n a v a i l a b l e   d u e   t o   n a t i o n a l   s h o r t a g e s ,   a n d   m a y   r a r e l y  
cause anaphylaxis (3, 8).  O u r   o b j e c t i v e   i s   t o   b r i n g   t o  
light the fact that although MBD is relatively safe, it is 
not without potential for serious complications. 
Methods 
The  2  patients  described  in  these  case  reports 
were seen at the University of Arizona Cancer Center 
during 2008 and referred to a breast surgical oncolo-
gist  for  further  care.  We  evaluated  and  managed 
complications of MBD injected by 2 referring surge-
ons for different indications. 
Case Report #1 
A  67-year-old woman with a T1b N0 M0 infil-
trating ductal carcinoma of the left breast was treated 
b y   a   s u r g e o n   a t   t h e   r e f e r r i n g   i n s t i t u t i o n :   s h e   u n d e r-
went a left segmental mastectomy and sentinel lymph 
n o d e   ( S L N )   b i o p s y   f o r   a   1 0   m m   p r i m a r y   t u m o r   l o-
cated at the 9 o’clock position.  The initial operating 
surgeon injected MBD in a subareolar subdermal fa-
shion, complicated by MBD skin necrosis. 
The  patient  initially  presented  describing  pain 
and tenderness of her left breast that persisted for two 
months  following  her  first  surgery.    We  observed 
volume loss of the left breast and nipple retraction.  
We noted a sinus in the 8 o’clock position, draining 
purulent fluid; erythema surrounding the areola, ex-
tending toward the axilla; and fluctuance in the cen-
tral breast.  On breast ultrasound examination, an area 
o f   l o c u l a t e d   f l u i d   w a s   d etected and drained percuta-
n e o u s l y .     C u l t u r e   r e s u l t s   o f   t h i s   f l u i d   s h o w e d   Coryne-
bacteria and anaerobic gram negative rods, which was 
clinically believed to be due to infection of the chronic 
o p e n   w o u n d   s e c o n d a r y   t o   M B D   n e c r o s i s .     T h e   p a t i e n t  
was  started  on  an  oral  antibiotic  regimen  without 
improvement.  
We  subsequently  admitted  the  patient  to  the 
hospital to perform an incision and drainage (I&D) of 
her left breast unresolving abscess cavity.  We made 
an incision in the area of maximal fluctuance in the 
lef t   b r e a s t   i n   t h e   p e r i a r e o l a r   r e g i o n   a t   5   o ’ c l o c k .     T o  
e x p l o r e   t h e   b o r d e r s   o f   t h e   c a v i t y ,   w e   u s e d   a   l a c r i m a l  
p r o b e ;   w e   n o t e d   t h a t   t h e   c a v i t y   w a s   c o n n e c t e d   t o   t h e  
sinus in the 8 o’clock position.  The cavity measured 
approximately 8cm x 7cm x 2.5cm and contained ne-
c r o t i c   t i s s u e .     T h e n ,   w e   m a d e   a   s e p a r a t e   i n c i s i o n   o v e r  
the sinus in the 8 o’clock position and completely ex-
c i s e d   t h e   t r a c t .     O n c e   w e   d e b r i d e d   t h e   c a v i t y ,   w e  
placed a wound vacuum-assisted  closure  (VAC)  de-
vice  for  negative  pressure  treatment  with  suction 
drainage (9, 10) through 2 separate incisions (Figures 
1-4).  
 
Figure 1:  The left breast exhibits nipple retraction, ery-
thema, and purulent drainage prior to incision and drainage. 
 
 
Figure  2:  The  probe  demonstrates  the  connection  be-
tween 2 draining chronic sinus tracts.  In the original op-
eration, methylene blue dye was injected in a subareolar 
fashion. 
 
 
F i g u r e   3 : After debridement of the chronic breast abscess, 
a single wound vacuum-assisted closure (VAC) sponge was 
p l a c e d   i n   t h e   c a v i t y ;   2   V A C   p a d s   w e r e   u s e d   t o   a p p l y   n e g a t i v e  
pressure therapy through the 2 separate incisions. Journal of Cancer 2011, 2 
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Figure 4:   T h e   b r e a s t   i s   s h o w n   a f t e r   w o u n d   V A C   s p o n g e  
removal and delayed primary closure over drains. Note the 
volume loss secondary to the MBD skin and breast necrosis.  
 
Case Report #2 
A  45-year-old  pre-menopausal  woman  under-
went  bilateral  breast  red u c t i o n s   p e r f o r m e d   b y   t h e  
r e f e r r i n g   s u r g e o n   i n   2 0 0 7 .     H e r   s u r g e r y   w a s   c o m p l i-
cated  by  Mycoplasma chelonae infection  secondary  to 
contaminated MBD.  She required multiple debride-
ments,  which  resulted  in  extensive  scar  tissue  and 
granuloma formation.   The U.S. Centers for Disease 
Control and Prevention (CDC) have reported conta-
mination of MBD with Mycobacteria chelonae in facelift 
patients  in  2003(11).     H o w e v e r ,   t o   o u r   k n o w l e d g e ,  
infectious  contamination  of  MBD  has not  been  pre-
viously reported in any breast surgery patients.  The 
p a t i e n t ’ s   p l a s t i c   s u r g e o n   t h a t   h a d   p r e v i o u s l y   p e r-
formed  her  breast  reductions  cultured  Mycobacteria 
chelonae directly from a contaminated bottle of MBD 
(personal  correspondence,  microbiology  reports).  
This  plastic  surgeon  had  a  series  of  24  Mycoplasma 
chelonae infections secondary to MBD on several of his 
cosmetic surgery patients during a period of 3 months 
in  2007  (personal  correspondence,  microbiology  re-
p o r t s ) .     T h i s   w a s   n e v e r   r e p o r t e d   t o   t h e   C D C   o r   e l s e-
where in the medical literature to date. 
Our  patient’s  follow-up  mammogram  showed 
distortion of the right breast in the upper quadrant, 
which was thought to be scarring from prior surgery, 
a l o n g   w i t h   a   s e p a r a t e   m a s s ,   l o c a t e d   i n   t h e   8   o ’ c l o ck 
p o s i t i o n ,   r e p o r t e d   w i t h   t h e   d i m e n s i o n s   o f   1 . 2   c m .     W e  
performed an ultrasound-g u i d e d   c o r e   b i o p s y   o f   t h a t  
mass and identified Nottingham grade 2 infiltrating 
lobular carcinoma with associated lobular carcinoma 
in situ.  
A   b i l a t e r a l   b r e a s t   m a g n e t i c   r e s o n a nce  imaging 
(MRI) showed a broad region (6.2 x 2.7cm) of abnor-
mal enhancement in the right breast, which was sus-
picious for lobular carcinoma (Figures 6-7 ) .     T o   e v a-
luate  the  extent  of  disease,  we  performed  3 
MRI-guided  core  biopsies:  2  were  negative  for  ma-
lignancy, and 1 revealed lobular carcinoma in situ. 
Thus, MRI was proven to overestimate her extent of 
d i s e a s e   s e c o n d a r y   t o   h e r   b r e a s t   i n f e c t i o n s   d u e   t o  
breast reduction. 
 
Figure  5: This photomicrograph shows tissue from the 
breast cavity. Note the foamy macrophages digesting dead 
adipocytes, indicating fat necrosis. The spaces between fat 
globules are filled by fibrosis. 
 
Figure 6:   N o t e   t h e   m e a s u r e m e n t s   o f   t h e   r i g h t   b r e a s t   m a s s  
per magnetic resonance imaging (MRI). 
 
Figure 7: Bilateral breast MRI with gadolinium depicts the 
prominent right breast mass which overestimated the ex-
t e n t   o f   d i s e a s e .     M R I   m e a s u r e d   t h e   m a s s   a t   6 . 2   x   2 . 7   c m .    
Pathology measured the tumor at 1.8 cm. Journal of Cancer 2011, 2 
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The  patient  elected  to  undergo  bilateral  total 
skin-sparing  mastectomies  and  right  axillary  SLN 
d i s s e c t i o n .     F i n a l   p a t h o l o g y   o f   t h e   r i g h t   b r e a s t   r e-
vealed a 1.8-cm, multifocal, grade 2, invasive lobular 
carcinoma with associated lobular carcinoma in situ.  
Margins were 2 cm from the tumor, with none of the 4 
SLNs involved.  Her Oncotype DX recurrence score 
w a s   1 9   ( i n t e r m e d i a t e   r i s k ) .     S h e   e n r o l l e d   i n   t h e   T r i a l  
Assigning  Individualized  Options  for  Treatment 
( T a i l o r   R X )   a n d   w a s   r a n d o m i z e d   t o   u n d e r g o   c h e m o-
therapy.  Her chronic lingering infection was an im-
portant factor in the decision to use systemic therapy 
with  cyclophosphamide,  methotrexate,  and 
5-fluorouracil (CMF), to avoid neutropenia.  Her his-
t o r y   o f   b i l a t e r a l   b r e a s t   i n f e c t i o n s   r e q u i r i n g   n u m e r o u s  
d e b r i d e m e n t s   a l s o   f a c t o r e d   i n t o   h e r   d e c i s i o n   m a k i n g  
to select bilateral mastectomies.  She has completed 
chemotherapy, underwent breast reconstruction and 
is maintained on tamoxifen hormonal therapy.  She 
eventually  successfully  completed  implant  based 
breast reconstruction. 
Discussion 
Surgical Considerations 
We are aware of only a few published complica-
tions of MBD in breast surgery patients (Table 1).  
 
 
Table 1.  Known Complications of Methylene Blue Dye in 
Breast Surgery 
Study   Surgical Proce-
dure  
Complications   Cases 
(n)  
Zakaria S et al (4)  Lymphatic map-
ping in breast 
cancer  
Local inflamma-
tion  
21  
        Skin necrosis   5  
        Blue staining   5  
        Wheal and flare   2  
Govaert GA et al 
(12) 
Lymphatic map-
ping in breast 
cancer  
Blue staining   33  
Stradling B et al (5)  Lymphatic map-
ping in breast 
cancer  
Skin necrosis   5  
Salhab M  et al (6)  Lymphatic map-
ping in breast 
cancer  
Skin and fat Ne-
crosis  
1  
Singh- 
Ranger G et al (14) 
Immediate re-
constructive 
breast surgery  
Capsular con-
traction  
1  
Varghese et al (1)  Lymphatic map-
ping in breast 
cancer 
Temporary Blue 
staining 
329 
Komenaka et al (13)  Lymphatic map-
ping in breast 
cancer 
Palpable mass at 
site of injection 
10 
 
 Varghese  et  al  (1),  described  safely  injecting 
M B D   i n   t h e   s u b d e r m a l   p l a n e   i n   t h e   s u b a r e o l a r   r e g i o n  
with 97.6% identification rate.  Their only reported 
complication  was  temporary  tattooing  from  MBD, 
w h i c h   w a s   a l s o   s e e n   o n   G o a v e r t   e t   a l   s e r i e s  (12).  Ma-
thelin et al (2) a n d   S o n i   e t   a l   (3) both used MBD safely 
without adverse reactions in SLN mapping.  Stradling 
et al (5) w a s   t h e   f i r s t   t o   d e s c r i b e   l o c a l   s k i n   r e a c t i o n s   t o  
MBD injection for SLN mapping, including skin ne-
crosis in 5 of 24 patients.  Zakaria et al (4) and Salhab 
et al (6) b o t h   r e p o r t e d   s k i n   a n d   f a t   n e c r o s i s   i n   a   s m a l l  
percentage of patients who received MBD injections 
f o r   S L N   m a p p i n g .     K o m e n a k a   e t   a l  (13) described a 
p a l p a b l e   m a s s   a t   t h e   s i t e   o f   i n j e c t i o n   o f   M B D .     N e a r l y  
a l l   o f   t h e   m a s s e s   r e s o l v e d   b y   o n e   y e a r ,   h o w e ver, one 
resolved  after  18  months.    None  of  the  aforemen-
tioned  patients  required  surgical  debridement.  
Singh–Ranger et al (14) d i d   r e p o r t   a   c o m p l i c a t i o n   t h a t  
required  surgical  revision.    They  reported  capsular 
contraction  associated  with  MBD,  after  immediate 
r e c o n s t r u c t i o n   u s i n g   b r e a s t   p r o s t h e s i s .     I n   t h e i r   c a s e  
they attributed local inflammatory reaction from the 
MBD as the main cause of the capsular contraction. 
Pathological Considerations 
One  of  our  patients  (Case  1)  presented  with  a 
well-d e v e l o p e d   r e g i o n   o f   f a t   n e c r o s i s   w i t h   c a v i t y  
formation.    Fat  necrosis  is  an  important  diagnostic 
consideration  as  it  may  persist  and  can  clinically 
mimic carcinoma. Early in its development, fat necro-
s i s   i s   c o m p o s e d   o f   d i s r u p t e d   f a t   c e l l s   a n d   h e m o r r h a g e  
w i t h   a n   i n f l u x   o f   h i s t i o c y t e s ,   s o m e   b e c o m i n g   m u l t i-
nucleate as they ingest debris.  After several weeks the 
affected area develops peripheral fibrosis, often with 
calcification and forming  a  tumor-like lesion which 
may clinically mimic carcinoma (15).  Attachment to 
the  skin,  dimpling  and  retraction  are  often  evident.  
C e n t r a l   c y s t i c   d e g e n e r a t i o n   m a y   a l s o   o c c u r   w i t h   r e-
s u l t a n t   c a v i t y   f o r m a t i o n .     T h i s   t y p e   o f   f a t   n e c r o s i s  
differs  from  fat  necrosis  caused  by  electrocautery.  
Electrocautery has evident thermal effect around the 
e d g e s   a n d   i n v o l v e d   a r e a s   a n d   d o e s   n o t   c a u s e   s u c h  
extensive destruction beyond the local tissue perime-
ter, with several centimeters of fat necrosis, as in the 
case of our patient. 
We are aware of 1 report of MBD contamination 
with  Mycobacteria  chelonae  that  caused  infections  in 
patients  who  had  undergone  facelifts  (11).     T o   o u r  
knowledge, our case represents the initial report of 
contaminated MBD in breast surgery patients.  This is 
of particular concern due to the impact that contami-
nated MBD had  on  the surgical and  adjuvant  man-
agement of breast cancer for our patients. Journal of Cancer 2011, 2 
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O u r   2   c a s e   r e p o r t s   c o n f i r m   t h e   f i n d i n g s   o f   p r e-
vious  publications  that  complications  of  MBD  are 
c a p a b l e   o f   c a u s i n g   t i s s u e   n e c r o s i s .     O f   n o t e ,   b o t h   o f  
our  patients  required  extensive  surgical  debride-
m e n t s ,   r e v e a l i n g   t h a t   M B D   d o e s   i n d e e d   h a v e   s i d e  
effects  not  considered  in  the  previously  published 
literature.  I n   o u r   C a s e   R e p o r t   # 2 ,   t h e   d i s c o v e r y   o f   a  
complicating  Mycobacterial  infection  led  to  delayed 
adjuvant treatment and had a significant impact on 
our choice for systemic treatment.   
T h e   s i t e   o f   i n j e c t i o n   o f   b l u e   d y e s   i s   s t i l l   c o n t r o-
versial.    Historically, Giuliano et al (16),    described 
u s i n g   b l u e   d y e   a s   p e r i t u m o r a l   i n j e c t i o n   w i t h   g o o d  
results; peritumoral in j e c t i o n   o f   b l u e   d y e   i s   t h e   m o s t  
c o m m o n   a p p r o a c h   t o   l y m p h a t i c   m a p p i n g   w i t h   v i t a l  
blue dyes.  Veronesi et al (17) injected blue dyes sub-
dermally.  Intradermal, periareolar or subareolar sites 
have also been described (18, 19).     T h e r e   a r e   a   l i m i t e d  
number  of  studies  indicating  high  success  rates  of 
identifying SLNs using subareolar injection of blue 
dye (20-22).  Rodier et al (23), using both blue dye and 
radiolabelled  isotope,  found  that  using  periareolar 
injection was equivalent to using peritumoral injec-
tion  in  identifying  SLN.    There  are  several  studies 
supporting the different sites of injection for blue dye, 
but  subareolar  and  dermal  injections  have  been 
proven to cause more local side effects, like discolora-
tion of the breast, that can last several months (24).   In 
our case it caused more than just discoloration but led 
to substantial tissue loss due to necrosis. 
Lymphazurin  had  long  been  held  as  the  stan-
d a r d   f o r   s e n t i n e l   l y m p h   n o d e   m a p p i n g   i n   b r e a s t   c a n-
cer(25).  However, MBD has demonstrated equivalent 
e f f i c a c y   i n   l y m p h a t i c   m a p p i n g   c o m p a r e d   t o   L y m-
phazurin  (3,  26-28),   i s   l e s s   e x p e n s i v e ,   m o r e   r e a d i l y  
a v a i l a b l e   a n d   i s   n o t   a s s o c i a t e d   w i t h   t h e   p o t entially 
deleterious side effects of severe allergic reaction, in-
cluding anaphylaxis (3, 8, 29) as has  been  reported 
with Lymphazurin.  Raut et al reported an incidence 
of severe anaphylactoid reaction to lymphazurin of 
1.1 %; preoperative prophylaxis reduced the severity, 
but not the overall incidence (0.5%) of adverse reac-
t i o n s   t o   L y m p h a z u r i n   b l u e   d y e   (30).  Blue urticaria 
and  facial  edema  were  the  reactions  observed  after 
preoperative prophylaxis in that study. 
A s   d e s c r i b e d   i n   t h e   a b o v e   c a s e s   a n d   t a b l e ,   M B D  
is  not  without  its  own  potential  for  complications.  
The risk for complications of MBD should be taken 
into  consideration  when  selecting  a  blue  dye  for 
lymphatic mapping.  Both MBD and Lymphazurin are 
vital blue dyes. Either may be used in combination 
with radioactive colloid and a gamma probe for sen-
tinel lymph node mapping.  According to the ASCO 
guidelines,  the  greatest  proportion  of  successful 
m a p p i n g s   a n d   t h e   l o w e s t   f a l s e   n e g a t i v e   r a t e s   a r e   a s-
sociated with the use of blue dye and radiolabelled 
colloid used in conjunction  (7).    However,  Golshan 
and colleagues (31) have  recently  published  data  to 
show that sentinel nodes can be successfully identi-
fied with MBD only.  Additionally, they recommend 
t h e   u s e   o f   M B D   o v e r   l y m p h a z u r i n ,   d u e   t o   t h e   l a t t e r ’ s  
known  potentially  deleterious  side  effects  of  severe 
allergic reaction, anaphylaxis or even death.   
Th e   d o s i n g   a n d   c o n c e n t r a t i o n   o f   M B D ,   i n   s u c-
cessful identification of SLN, has been described as 1 - 
5 milliliters (ml) of 1% methylene blue (3, 5, 31) or 
1.25mg/ml (2, 4).  We recommend using dilute MBD 
based on our institutional experience with this medi-
cation. MBD may indeed become the most prevalent 
vital blue dye for these reasons and due to intermit-
tent national shortages of Lymphazurin blue dye (3).  
The  importance  of  understanding  its  proper  usage 
and potential complications, therefore, cannot be un-
derstated.   
Conclusions 
T h e   u s e   o f   M B D   i n   b r e a s t   s u r g e r y   p a t i e n t s   i s   n o t  
without  risk.    I n   b o t h   o f   t h e s e   p a t i e n t s ,   M B D   w a s  
integral to complications requiring surgical debride-
m e n t s   f o r   l o c a l   w o u n d   p r o b l e m s .     I n   e a c h   p a t i e n t ’ s  
case,  severe  necrosis  and  infection  were  present.  
Awareness should be raised regarding MBD’s poten-
tial  to  elicit  tissue  necrosis  resulting  in  significant 
morbidity,  cosmetically  unsatisfactory  results  and 
even delayed cancer treatment.   
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